Immediate Impact

2 from Science/Nature 49 standout
Sub-graph 1 of 24

Citing Papers

NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial
2023 Standout
Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations
2022 Standout
2 intermediate papers

Works of F Turpin being referenced

A phase I clinical and pharmacokinetic study of capecitabine (Xeloda®) and irinotecan combination therapy (XELIRI) in patients with metastatic gastrointestinal tumours
2005
Phase II trial of vinorelbine/doxorubicin as first-line therapy of advanced breast cancer.
1994

Author Peers

Author Last Decade Papers Cites
F Turpin 243 8 40 82 81 33 397
Greenspan Em 154 17 20 68 66 23 397
V. K. Vaitkevicius 163 24 30 87 49 22 436
M Namer 266 3 49 92 84 36 432
C. L. Vogel 264 4 32 57 89 27 404
Ewa Chmielowska 245 3 26 106 57 42 455
S. C. Remick 232 18 24 139 55 25 398
Alex Y. C. Chang 169 12 33 129 62 24 422
Mitsuru Yoshimoto 177 23 26 135 140 37 425
Sumie Hiramatsu 139 30 48 98 60 36 458
Bill L. Tranum 231 15 37 46 137 20 422

All Works

Loading papers...

Rankless by CCL
2026